San Francisco startup Structure Therapeutics is also engaged on an oral, once-everyday GLP-1 drug called GSBR-1290—the drug surpassed Wall Street’s expectations in June any time a mid-stage examine confirmed ordinary weight loss of about 6% and it strategies to start An additional mid-stage trial toward the end of this yr—that founder and CEO